Hormone Receptor-Positive Breast Carcinoma

Hormone Receptor-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 36
Recruiting: 25
Ph III recruiting: 3
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04789668	Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases	terminated	Phase 1 / Phase 2	8	M.D. Anderson Cancer CenterOTHER	1	Mar 18, 2026	clinicaltrials
NCT05554354	Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)	terminated	Phase 2	1	National Cancer Institute (NCI)NIH	2	Mar 3, 2026